McGrane, D., Fisher, M. and McKay, G. A. (2011) Drugs for diabetes: part 3 thiazolidinediones. British Journal of Cardiology, 18(1), pp. 24-27.
Full text not currently available from Enlighten.
Publisher's URL: http://bjcardio.co.uk/2011/02/drugs-for-diabetes-part-3-thiazolidinediones/
Abstract
Thiazolidinediones (glitazones) are a relatively new addition to the type 2 diabetes drug armoury, but they have caused considerable controversy since they were introduced into the routine management of patients with type 2 diabetes. Until recently there were two thiazolidinediones licensed for use in the treatment of type 2 diabetes: rosiglitazone and pioglitazone, but the European Medicines Agency (EMEA) on the 23rd September 2010 removed rosiglitazone’s marketing authorisation across Europe because of concerns about cardiovascular safety. There is no evidence to show a similar cardiovascular safety concern for pioglitazone, apart from increased fluid retention and reported heart failure. Pioglitazone may still have a therapeutic role in the management of selected patients.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McKay, Dr Gerard |
| Authors: | McGrane, D., Fisher, M., and McKay, G. A. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing |
| Journal Name: | British Journal of Cardiology |
| Journal Abbr.: | Br J Cardiol |
| Publisher: | MediNews Limited |
| ISSN: | 0969-6113 |
| ISSN (Online): | 1753-4313 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details